A simulation model of the within-host dynamics of Plasmodium vivax infection

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Kerlin, Douglas H ^a   Gatton, Michelle L ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Hypnozoite; Plasmodium vivax; Preferential invasion; Simulation model; Within host dynamics

Indexed keywords

ANTIGENIC VARIATION; ARTICLE; CELL INVASION; ERYTHROCYTE; FEMALE; FEVER; GAMETOCYTE; HOST PARASITE INTERACTION; HUMAN; HYPNOZOITES; IMMUNE RESPONSE; MALE; MEROZOITE; NEUROSYPHILIS; PARASITE LOAD; PARASITE SURVIVAL; PLASMODIUM (LIFE CYCLE STAGE); PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX MALARIA; RETICULOCYTE; SCHIZONT; SEX DIFFERENCE; SEX RATIO; SIMULATION; TIME SERIES ANALYSIS; COMPUTER SIMULATION; GROWTH, DEVELOPMENT AND AGING; PARASITOLOGY; PLASMODIUM VIVAX; STATISTICAL MODEL; TIME FACTOR;

COMPUTER SIMULATION; FEMALE; HUMANS; MALARIA, VIVAX; MALE; MODELS, STATISTICAL; PLASMODIUM VIVAX; TIME FACTORS;

EID: 84928736360     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0580-z     Document Type: Article

References (43)

1. Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg. 2001;64:97-106.
2. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: Neglected and not benign. Am J Trop Med Hyg. 2007;77:79-87.
3. Gogia A, Kakar A, Byotra SP. Is benign tertian malaria actually benign? Trop Doct. 2012;42:92-3.
4. Singh H, Parakh A, Basu S, Rath B. Plasmodium vivax malaria: Is it actually benign? J Infect Public Health. 2011;4:91-5.
5. Trager W, Jensen JB. Human malaria parasites in continuous culture. Science. 1976;193:673-5.
6. Trager W, Jensen JB. Continuous culture of Plasmodium falciparum: its impact on malaria research. Int J Parasitol. 1997;27:989-1006.
7. Garnham P C C. Malaria parasites and other haemosporidia. Oxford: Blackwell; 1966.
8. White NJ. Malaria. In: Cook GC, Zumla AI, editors. Manson's Tropical Diseases. 22nd ed. Edinburgh: Saunders Ltd; 2009.
9. Kerlin D, Gatton M. Preferential invasion by Plasmodium merozoites and the self-regulation of parasite burden. PLoS One. 2013;6:e57434.
10. Global Malaria Programme WHO. World Malaria Report 2012. Geneva: World Health Organization; 2012.
11. Anstey NM, Russell B, Yeo TW, Price RN. The pathophysiology of vivax malaria. Trends Parasitol. 2009;25:220-7.
12. Bousema T, Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev. 2011;24:377-410.
13. Bull PC, Berriman M, Kyes S, Quail MA, Hall N, Kortok MM, et al. Plasmodium falciparum variant surface antigen expression patterns during malaria. PLoS Pathog. 2005;1:202-13.
14. Gatton ML, Cheng Q. Investigating antigenic variation and other parasite-host interactions in Plasmodium falciparum infections in naïve hosts. Parasitology. 2004;128:367-76.
15. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, et al. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis. 2009;9:555-66.
16. Cogswell FB. The hypnozoite and relapse in primate malaria. Clin Microbiol Rev. 1992;5:26-35.
17. Krotoski WA. Discovery of the hypnozoite and a new theory of malarial relapse. Trans R Soc Trop Med Hyg. 1985;79:1-11.
18. Huldén L, Huldén L, Heliovaara K. Natural relapses in vivax malaria induced by Anopheles mosquitoes. Malar J. 2008;7:64.
19. Nishiura H, Lee HW, Cho SH, Lee WG, In TS, Moon SU, et al. Estimates of short- and long-term incubation periods of Plasmodium vivax malaria in the Republic of Korea. Trans R Soc Trop Med Hyg. 2007;101:338-43.
20. Huldén L, Huldén L. Activation of the hypnozoite: a part of Plasmodium vivax life cycle and survival. Malar J. 2011;10:90.
21. McKenzie FE, Jeffery GM, Collins WE. Plasmodium vivax blood-stage dynamics. J Parasitol. 2002;88:521-35.
22. Kerlin DH, Boyce K, Marfurt J, Simpson JA, Kenangalem E, Cheng Q, et al. An analytical method for assessing stage-specific drug activity in Plasmodium vivax malaria: Implications for ex vivo drug susceptibility testing. PLoS Negl Trop Dis. 2012;6:e1772.
23. Gatton ML, Cheng Q. Interrupting malaria transmission: quantifying the impact of interventions in regions of low to moderate transmission. PLoS One. 2010;5:e15149.
24. Karyana M, Burdarm L, Yeung S, Kenangalem E, Wariker N, Maristela R, et al. Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum. Malar J. 2008;7:148.
25. Lin E, Kiniboro B, Gray L, Dobbie S, Robinson L, Laumaea A, et al. Differential patterns of infection and disease with P falciparum and P vivax in young Papua New Guinean children. PLoS One. 2010;5:e9047.
26. Luxemburger C, Ricci F, Nosten F, Raimond D, Bathet S, White NJ. The epidemiology of severe malaria in an area of low transmission in Thailand. Trans R Soc Trop Med Hyg. 1997;91:256-62.
27. Gatton ML, Cheng Q. Evaluation of the pyrogenic threshold for Plasmodium falciparum malaria in naive individuals. Am J Trop Med Hyg. 2002;66:467-73.
28. Carter R, Graves PM. Gametocytes. In: Wernssdorfer WH, McGregor I, editors. Malaria Principles and Practice of Malariology, vol. 1. Edinburgh: Churchill Livingstone; 1988. p. 253-305.
29. Kwiatkowski D. Febrile temperatures can synchronize the growth of Plasmodium falciparum in vitro. J Exp Med. 1989;169:357-61.
30. McClean CM, Alvarado HG, Neyra V, Llanos-Cuentas A, Vinetz JM. Optimized in vitro production of Plasmodium vivax ookinetes. Am J Trop Med Hyg. 2010;83:1183-6.
31. Mason DP, McKenzie FE. Blood-stage dynamics and clinical implications of mixed Plasmodium vivax-Plasmodium falciparum infections. Am J Trop Med Hyg. 1999;61:367-74.
32. Boyd MF, Kitchen SF. On the infectiousness of patients infected with Plasmodium vivax and Plasmodium falciparum. Am J Trop Med Hyg. 1937; s1-17:253-62.
33. Coatney G, Collins W, Warren M, Contacos P. The Primate Malarias. Bethesda MD: Department of Health, Education and Welfare; 1971.
34. Mackerras MJ, Ercole QN. Some observations on the action of quinine, atebrin, and plasmoquine on Plasmodium vivax. Trans R Soc Trop Med Hyg. 1949;42:443-54.
35. Jeffery GM. Infectivity to mosquitoes of Plasmodium vivax following treatment with chloroquine and other antimalarials. Am J Trop Med Hyg. 1958;7:207-11.
36. Gatton ML, Cheng Q. Plasmodium falciparum infection dynamics and transmission potential following treatment with sulfadoxine-pyrimethamine. J Antimicrob Chemother. 2006;58:47-51.
37. Pichon G, Awono-Amebe HP, Robert V. High heterogeneity in the number of Plasmodium falciparum gametocytes in the bloodmeal of mosquitoes fed on the same host. Parasitology. 2000;121:115-20.
38. Baird JK, Leksana B, Masbar S, Fryauff DJ, Sutanihardja MA, Suradi, et al. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg. 1997;56:621-6.
39. Battle KE, Karhunen MS, Bhatt S, Gething PW, Howes RE, Golding N, et al. Geographical variation in Plasmodium vivax relapse. Malar J. 2014;13:144.
40. Ehrman FC, Ellis JM, Young MD. Plasmodium vivax Chesson strain. Science. 1945;101:377.
41. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2011.
42. Chen NH, Auliff A, Rieckmann K, Gatton M, Cheng Q. Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. J Infect Dis. 2007;195:934-41.
43. Ishikawa H, Ishii A, Nagai N, Ohmae H, Harada M, Suguri S, et al. A mathematical model for the transmission of Plasmodium vivax malaria. Parasitol Int. 2003;52:81-93.